Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21st 2020

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Schmaier on Managing Cancer-Associated Thrombosis

April 17th 2020

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Dr. Bradley on Evolving Therapeutic Strategies in MPNs

April 17th 2020

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Mesa Provides Perspective on Diagnosis and Treatment in Essential Thrombocythemia

April 15th 2020

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.

Managing Treatment Toxicity in CML and MPNs

April 14th 2020

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Dr. Pemmaraju on the Need for Collaboration in Myelofibrosis

April 14th 2020

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis

April 11th 2020

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis

April 10th 2020

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment

April 10th 2020

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

Dr. Snyder on Tools to Improve Use of Allogeneic Stem Cell Transplant in Myelofibrosis

April 8th 2020

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Dr. Jain on High-Risk Mutations in Myelofibrosis

April 8th 2020

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

April 8th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Dr. Mesa on Challenges in Myelofibrosis Treatment

April 8th 2020

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

A Treatment Option in Myelofibrosis

April 7th 2020

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

Dr. Cortes on the Safety Profile of Ruxolitinib in MPNs

April 7th 2020

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

MDS Armamentarium Expands With Luspatercept Approval, Novel Compounds

April 7th 2020

David P. Steensma, MD, discusses some new data in myelodysplastic syndromes and ongoing research in the space.

Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

April 3rd 2020

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis

March 28th 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

March 26th 2020

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.